Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 3

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 3
---
 with, and none has given any commitment or assurance to each other or any other person as to how she or he, will act or vote on any issue or question. Each such person will fulfill his or her fiduciary duty in determining how to vote on any issue that comes before the Board of Directors. The Nominees have vast and diverse experience and skills that would be of significant value to the Company and bring new perspectives and ideas to improve the Company’s performance: Mr. Travis C. Mickle, PhD, has over 25 years of pharmaceutical industry experience, including founding the Company, serving as President and Chief Executive Officer of Zevra from 2010 to 2023, and leading the development of multiple approved products. His expertise spans drug discovery, regulatory strategy, corporate finance, and pharmaceutical commercialization. Mr. Arthur C. Regan serves as President & CEO of Regan & Associates, Inc. a New York, New York based proxy solicitation/shareholder services firm founded by him in 1991, and previously held various management roles. Mr. Regan has organizational and leadership skills that would be useful to the Company in establishing a Board of Directors who are committed to best practices in governance and executive compensation. Mr. Mangless believes that the election of these two highly qualified Nominees to Zevra’s Board rather than the persons nominated by the Board is a critical step to ensure that Zevra is on the right path to maximize value for all stockholders. The Nominees are committed to rigorous oversight of Zevra’s management, operations and business strategy, and to ensuring that Zevra conducts its business for greater benefit for stockholders. Mr. Mangless is seeking your support to elect the Nominees. More information about the candidates, including the names, background and qualifications of the Nominees is contained in the enclosed proxy statement. There is no assurance that any of the Company’s nominees will serve as directors if the Nominees are elected. This Proxy Statement is first being sent or given to stockholders on or about [●], 2025. If your shares are held in your own name, please authorize a proxy to vote by signing and returning the enclosed BLUEuniversal proxy card in the postage-paid envelope provided or by instructing us by telephone or via the Internet as to how you would like your shares of Common Stock voted (instructions are on your BLUEuniversal proxy card). The Proponent asks that you cast your votes FORMr. Travis C. Mickle, PhD and Mr